Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1680367 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $6.76Day −0.88%Mkt cap $518M1Y +709.6%Off 52W high −18.8%Vol (1Y) 103.5%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,360 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest10.2% of sh out |
| Days to cover5.8d |
| 13F net flow (QoQ)+14.84% |
| Top-10 13F concentration73.9% |
| Next report (est.)2026-08-06 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$1.0M |
| Earnings (TTM)-$49.9M |
| ROE−60.3% |
| Net margin−4880.9% |
| Sales growth 3Y15.3% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+85.2% |
| 1Y+709.6% |
| 3Y+165.1% |
| 5Y−69.1% |
| Since incept. (ann.)−29.0% |
Total return through 2026-07-29 · series begins 2021-02-22. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)103.5% |
| Ann. volatility (3Y)139.0% |
| Sharpe (1Y)2.58 |
| Sharpe (3Y)0.82 |
| Max drawdown (1Y)−50.5% |
| Max drawdown (3Y)−93.5% |
| Beta (3Y vs SPY)1.48 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 9.9M | $63M | 12.87% | +430.1% |
| ORBIMED ADVISORS LLC | 6.3M | $41M | 8.22% | +0.0% |
| Redmile Group, LLC | 5.5M | $36M | 7.22% | +0.0% |
| Prosight Management, LP | 5.0M | $32M | 6.53% | +110.1% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 4.6M | $30M | 6.06% | −26.3% |
| NEXTBio Capital Management LP | 3.1M | $20M | 4.11% | +0.0% |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.3M | $15M | 2.97% | new |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.8M | $11M | 2.32% | −7.4% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-07 | −$0.13 | — | $0 | — |
| 2025-12-31 | 2026-03-05 | — | — | $0 | — |
| 2025-09-30 | 2025-11-06 | −$0.14 | — | $1.0M | −66.6% |
| 2025-06-30 | 2025-08-14 | −$0.24 | — | $0 | −100.0% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-06 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
Reportable 100%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
